The Severity of Symptoms after Preparation for Colonoscopy in Irritable Bowel Syndromes

Document Type : Original Article (s)

Authors

1 Gastroenterologist, Internal Medicine Group, Isfahan Gastroenterology and Hepatology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

2 Internal Medicine Resident, Internal Medicine Group, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: The use of laxatives reduces the symptoms of irritable bowel syndrome (IBS) due to the change in intestinal microbial flora. Reduction of worry and anxiety after colonoscopy can play a role in reducing symptoms in these patients. This study was conducted to investigate the changes in the symptoms in IBS patients in the short, medium, and long term after colonoscopy.
Methods: In this descriptive study, 70 IBS patients who were candidates for colonoscopy were selected. The severity of symptoms of IBS was evaluated before colonoscopy and at intervals of one, four, and twelve after colonoscopy using the ROMEIV criteria and IBSSS questionnaire. The changes in the severity of the disease during the studied intervals were analyzed. Since receiving preparations is unpleasant for patients, therefore, the control group was not considered.
Findings: The average score of IBS severity before colonoscopy was 296.71 ± 87.2. One,4 and 12 weeks after colonoscopy was 226.9 ± 85.8, 191.1 ± 88.4, and 154.1 ± 84.8 respectively, compared to before treatment, the mean difference was 142.6±85.4 and the trend of IBS severity changes showed a significant decrease during
12 weeks after colonoscopy (P < 0.001).
Conclusion: Colonoscopy in patients with irritable bowel syndrome not only does not aggravate the symptoms of the disease, but also reduces the symptoms, and performing this procedure should not be avoided in those who have indications for colonoscopy.

Highlights

Mohammad Jafari: Google Scholar

Maryam Soheilipour: PubMed ,Google Scholar

Elham Tabesh: PubMed ,Google Scholar

Zohre Mirbeik Sabzevari :PubMed , Google Scholar

Peyman Adibi: PubMed , Google Scholar

Keywords

Main Subjects

References

  1. Shah SL, Janisch NH, Crowell M, Lacy BE. Patients with irritable bowel syndrome are willing to take substantial medication risks for symptom relief. Clin Gastroenterol Hepatol 2020; 19(1): 80-6.
  2. Ballou S, McMahon C, Lee H-N, Katon J, Shin A, Rangan V, et al. Effects of irritable bowel syndrome on daily activities vary among subtypes based on results from the IBS in America Survey. Clin Gastroenterol Hepatol 2019; 17(12): 2471-8. e3.
  3. Grad S, Dumitrascu DL. Irritable bowelsyndrome subtypes: new names for old medical conditions. Dig Dis 2020; 38(2): 122-7.
  4. Meyer GW. Esophageal symptoms are not related to abnormal motor function. Am J Gastroenterol 2014; 109(11): 1831.
  5. Spiegel BMR, Gralnek IM, Bolus R, Chang L, Dulai GS, Naliboff B, et al. Is a negative colonoscopy associated with reassurance or improved health-related quality of life in irritable bowel syndrome? Gastrointest Endosc 2005; 62(6): 892-9.
  6. Huang HL, Chen HT, Luo QL, Xu HM, He J, Li YQ, et al. Relief of irritable bowel syndrome by fecal microbiota transplantation is associated with changes in diversity and composition of the gut microbiota. J Dig Dis 2019; 20(8): 401-8.
  7. Enck P, Mazurak N. Dysbiosis in functional bowel disorders. Ann Nutr Metab 2018; 72(4): 296-306.
  8. Lee YY, Annamalai C, Rao SSC. Post-infectious irritable bowel syndrome. Curr Gastroenterol Rep 2017; 19(11): 56-9.
  9. Chen J, Spear SK, Huddleston JG, Rogers RD. Polyethylene glycol and solutions of polyethylene glycol as green reaction media. Green Chemistry 2005; 7(2): 64-82.
  10. Guo R, Chen L-H, Xing C, Liu T. Pain regulation by gut microbiota: molecular mechanisms and therapeutic potential. Br J Anaesth 2019; 123(5): 637-54.
  11. Saeed F, Salehi M, Alavi K, Ajdarkosh H, Kashaninasab F, Esfahani F. Defense mechanisms in patients with irritable bowel syndrome and their relationship with symptom severity and quality of life. Middle East J Dig Dis 2019; 11(3): 158-62.
  12. Awad R, Camacho S. A randomized, double‐blind, placebo‐controlled trial of polyethylene glycol effects on fasting and postprandial rectal sensitivity and symptoms in hypersensitive constipation‐predominant irritable bowel syndrome. Colorectal Dis 2010; 12(11): 1131-8.
  13. Khoshoo V, Armstead C, Landry L. Effect of a laxative with and without tegaserod in adolescents with constipation predominant irritable bowel syndrome. Aliment Pharmacol Ther 2006; 23(1): 191-6.
  14. Chapman R, Stanghellini V, Geraint M, Halphen M. Randomized clinical trial: macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome. Am J Gastroenterol 2013; 108(9): 1508-15.
  15. Di Palma JA, Smith JR, vB Cleveland M. Overnight efficacy of polyethylene glycol laxative. Am J Gastroenterol 2002; 97(7): 1776-9.
  16. Anderson J, Edney R, Whelan K. Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease. Aliment Pharmacol Ther 2012; 36(6): 503-16.
  17. O'Mahony SM, Dinan TG, Cryan JF. The gut microbiota as a key regulator of visceral pain. Pain 2017; 158(Suppl 1): S19-S28.
Journal of Isfahan Medical School
Volume 41, Issue 738
2nd Week, December
November and December 2023
Pages 866-871

Files

History

  • Receive Date: 03 June 2023
  • Accept Date: 04 December 2023

Share

How to cite

Statistics